Wealthspire Advisors LLC Sells 1,137 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Wealthspire Advisors LLC lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,601 shares of the medical equipment provider’s stock after selling 1,137 shares during the period. Wealthspire Advisors LLC’s holdings in Zimmer Biomet were worth $803,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth approximately $35,000. Finally, Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $107.54 on Wednesday. The company has a 50 day moving average of $105.83 and a 200 day moving average of $107.44. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The firm has a market cap of $21.41 billion, a P/E ratio of 24.17, a PEG ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company earned $2.20 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is presently 21.57%.

Analysts Set New Price Targets

Several research firms recently weighed in on ZBH. Barclays cut their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, Raymond James dropped their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.